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Abstract
Introduction: Sunitinib, an oral multitargeted tyrosine kinase inhibitor, is widely used in the treatment of renal cell
carcinoma and gastrointestinal stromal tumor and has had a variety of adverse events. However, sunitinib-related
acute cholecystitis has been reported in only two patients with gastrointestinal stromal tumor and renal cell
carcinoma (clear cell subtype).
Case presentation: A 75-year-old Japanese woman with a right sided abdominal swelling was referred to our
hospital. Computed tomography (CT) showed a hypervascular bulky tumor in her right kidney, suggesting right
renal cell carcinoma in clinical T4N0M0. Although sunitinib therapy was started as neoadjuvant chemotherapy,
during the fourth week of the first cycle, she developed acute acalculous cholecystitis and disseminated
intravascular coagulation associated with sunitinib. Sunitinib therapy was discontinued immediately and she
recovered after subsequent treatment with antibiotics and gabexate mesilate followed by percutaneous
cholecystostomy. Cholecystectomy and right radical nephrectomy were performed and pathological examination
showed that her renal tumor was a chromophobe renal cell carcinoma (pT2) with necrosis. Inflammation and
ischemia were observed in the gallbladder wall, which was compatible with acute acalculous cholecystitis. There
has been no evidence of disease recurrence for more than six months.
Conclusion: We described the third case of sunitinib-related acute cholecystitis in a patient with chromophobe
renal cell carcinoma. Attention is required to sunitinib-related acute cholecystitis which, while uncommon, could
be life-threatening.
Introduction
Sunitinib, an oral multitargeted tyrosine kinase inhibitor,
is widely used in the treatment of metastatic renal cell
carcinoma (RCC) and gastrointestinal stromal tumor
(GIST) and has been administered in the perioperative
period [1]. Although sunitinib has had a variety of
adverse events, sunitinib-related acute cholecystitis has
been reported in only two patients with GIST and RCC
(clear cell subtype). We report a third case of sunitinib-
related acute cholecystitis in a patient with chromo-
phobe RCC who developed a serious condition.
Case presentation
A 75-year-old Japanese woman with a right sided
abdominal swelling was referred to our hospital. She
had no history of medication or smoking and was a
social drinker. Computed tomography (CT) showed a
hypervascular bulky tumor in her right kidney with sus-
pected liver invasion without distant metastasis (Figure
1), suggesting right RCC in clinical T4N0M0. For the
purpose of downstaging of the tumor, sunitinib therapy
(50 mg per day, four weeks on and two weeks off) was
started in the neoadjuvant setting. During the fourth
week of the first cycle, she experienced right upper
quadrant pain with a positive Murphy’ss i g na n d
abdominal fullness without fever. Laboratory tests
revealed elevated levels of C-reactive protein, lactate
dehydrogenase, and liver transaminases although total
bilirubin, alkaline phosphatase, and amylase were at
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any medium, provided the original work is properly cited.normal levels. She also had laboratory features of disse-
minated intravascular coagulation (DIC) including
thrombocytopenia and disordered coagulation. Despite a
normal gallbladder at the first visit (Figure 2), abdominal
computed tomography (CT) revealed a tense and dilated
gallbladder and thickening of the gallbladder wall with-
out gallbladder stones or emphysematous change (Figure
3). Based on the diagnosis of acute acalculous cholecys-
titis associated with sunitinib, sunitinib therapy was dis-
continued immediately. She recovered in an intensive
care unit after subsequent treatment with antibiotics
and gabexate mesilate (FOY
®) followed by percutaneous
cholecystostomy.
After three months, a follow-up contrast-enhanced
computed tomography (CT) revealed a marked shrink-
age of the gallbladder and a 21% reduction in the size of
the renal tumor with decreased enhancement of its
center. Cholecystectomy and right radical open
nephrectomy were performed. Adhesions thought to be
due to cholecystitis made the operation difficult
although common bile duct stenosis or retraction by the
tumor that could lead to cholecystitis was not observed.
Pathological examination showed that her renal tumor
was chromophobe RCC (pT2) with necrosis occupying
more than half of the tumor (Figure 4). Inflammation
and ischemia were observed in the gallbladder wall
which was compatible with acute acalculous cholecystitis
(Figure 5). Computed tomography (CT) has revealed no
evidence of disease recurrence for more than six months
since the radical nephrectomy.
Discussion
We present the third case of sunitinib-related acute cho-
lecystitis which developed in a patient with a
g
Figure 1 Abdominal CT showed right renal mass, suggestive of
RCC at the first visit.
Figure 2 Abdominal CT showed a normal gallbladder at the
first visit.
Figure 3 Abdominal CT showed acalculous cholecystitis during
the fourth week of the first cycle of sunitinib therapy.
Figure 4 Chromophobe renal cell carcinoma (RCC) (blue arrow)
with necrosis (yellow arrow).
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acute cholecystitis has been reported in only two other
patients, one with GIST [2] and the other with RCC
(clear cell subtype) [3]. We evaluated whether or not
acute cholecystitis in our patient was caused by sunitinib
with the use of the Naranjo scale [4] which assesses the
probability of a drug-related adverse event [2,3]. Its
scale score for our patient was five (Table 1), indicating
a probable association of acute cholecystitis with suniti-
nib. Sunitinib-related acute cholecystitis was also sup-
ported by the following findings: the symptoms
improved with discontinuation of sunitinib; there were
no risk factors including gallbladder stones, common
bile duct stenosis and other hepatobiliary diseases that
could cause acute cholecystitis and deranged liver
function.
A common clinical feature of sunitinib-related acute
cholecystitis in three cases including our patient and the
previous two cases [2,3] was acalculous cholecystitis
while gallbladder stones have been found in 90% of
patients with acute cholecystitis [5]. On the other hand,
sunitinib causes vascular adverse events by vascular
endothelial dysfunction [6,7] resulting in myocardial
ischemia [8] and proteinuria due to renal thrombotic
microangiopathy [9]. Likewise, sunitinib-related acute
cholecystitis might be caused by the antivascular effect
of sunitinib rather than gallbladder stones although the
detailed mechanism underlying this adverse event is
unclear. As sunitinib is widely used in the treatment of
RCC and GIST, we need to pay attention to sunitinib-
related acute cholecystitis which, while uncommon,
could be life-threatening.
Conclusion
We described the third case of sunitinib-related acute
cholecystitis in a patient with chromophobe RCC.
Attention needs to be given to sunitinib-related acute
cholecystitis which could be life-threatening albeit
uncommon.
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Figure 5 Gallbladder epithelium showed inflammation with
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Table 1 Adverse drug reaction probability scale (Naranjo Scale) in the present case
Yes No Don’t know Score
1. Are there previous conclusive reports on this reaction? ✓ 0
2. Did the adverse event appear after the suspected drug was given? ✓ 2
3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? ✓ 0
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